Private company

Q BioMed Inc.

American pharmaceutical preparations company, incorporated in Nevada¹

In its 2023 annual report the company says: “We are a commercial stage biotechnology acceleration and development company focused on acquiring and in-licensing pre-clinical, clinical-stage and approved life sciences therapeutic products. Our model seeks to diversify risk by broadening the therapeutic areas we work in as well as providing multiple catalysts as we advance assets through the clinical and regulatory process.”²⁴ It is headquartered in New York, New York.¹

Last updated Oct 20, 2026.

Overview

IndustryPharmaceutical Preparations¹
HeadquartersNew York, New York¹
Incorporated inNV²
Business address366 Madison Ave., 3Rd Floor, New York, Ny 10017²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-3.2%Gross margin³

-1211.7%Operating margin³

-721.7%Net margin³

45.4%Revenue growth, 2022³

Where the money goes

Where each dollar of revenue went, fiscal 2022

Cost of revenueInterest

Cost of revenue16¢$293.3K
Research and development7¢$125.4K
Interest77¢$1.4M

Out of $284.4K in revenue.³ The company lost money this year.

Where each dollar of operating cash went, fiscal 2022

Kept or used elsewhere

Kept or used elsewhere100¢$1.9M

Out of $1.9M of cash from operations.³

Financial statements

Revenue⁴³$284.4K in 2022+848% since 2020

Gross profit⁴³-$9.0K in 2022−97% since 2020

Operating income³-$3.4M in 2022−53% since 2021

Net income⁵⁶⁷⁸⁴³-$2.1M in 2022−71% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Revenue					$30.0K⁴	$195.6K³	$284.4K³
Cost of revenue					$326.0K⁴	$246.8K³	$293.3K³
Gross profit					-$296.0K⁴	-$51.2K³	-$9.0K³
Research and development	$1.3M⁵	$3.1M⁶	$3.2M⁷	$3.5M⁸	$1.9M⁴	$1.1M³	$125.4K³
Selling, general and admin
Operating expenses						$7.3M³	$3.4M³
Operating income						-$7.4M³	-$3.4M³
Interest	$480.3K⁵	$760.3K⁵	$162.1K⁷	$1.5M⁸	$296.2K⁴	$506.9K³	$1.4M³
Income before tax						-$7.4M⁴
Net income	-$7.2M⁵	-$14.5M⁶	-$9.3M⁷	-$10.3M⁸	-$13.5M⁴	-$8.2M³	-$2.1M³
Earnings per share					-$0.65⁴	-$0.33³	-$0.08³
Earnings per share (diluted)					-$0.65⁴	-$0.33³	-$0.08³
Shares (weighted, basic)						26.8M shares³	44.8M shares³
Shares (weighted, diluted)						26.8M shares³	44.8M shares³

Total assets⁵⁶⁷⁸⁴³$3.5M in 2022+139% since 2016

Total liabilities⁵⁶⁷⁸⁴³$8.1M in 2022+132% since 2016

Shareholders’ equity⁶⁷⁸⁴³-$4.6M in 2022+126% since 2016

Cash⁶⁷⁸³$50.0K in 2022−97% since 2016

Long-term debt⁷⁸$447.3K in 2019−84% since 2018

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash	$1.5M⁶	$824.8K⁷	$2.7M⁸	$172.6K⁸	$177.1K⁸	$344.0K³	$50.0K³
Receivables						$80.1K³	$11.5K³
Inventory						$22.3K³
Current assets	$1.5M⁵	$827.3K⁶	$2.7M⁷	$190.3K⁸	$223.5K⁴	$459.5K³	$72.3K³
Intangible assets						$350.0K³	$300.0K³
Total assets	$1.5M⁵	$827.3K⁶	$3.2M⁷	$640.3K⁸	$623.5K⁴	$809.5K³	$3.5M³
Accounts payable						$1.3M³	$2.1M³
Short-term debt						$3.1M³	$4.1M³
Current liabilities	$3.3M⁵	$471.0K⁶	$429.4K⁷	$5.2M⁸	$1.7M⁴	$5.5M³	$8.1M³
Long-term debt			$2.9M⁷	$447.3K⁸
Total liabilities	$3.5M⁵	$471.0K⁶	$3.3M⁷	$5.7M⁸	$1.7M⁴	$5.5M³	$8.1M³
Retained earnings						-$64.1M³	-$66.1M³
Shareholders’ equity	-$2.0M⁶	$356.2K⁷	-$105.7K⁸	-$5.0M⁴	-$1.1M³	-$4.7M³	-$4.6M³
Shares outstanding	9.2M shares⁵	12.2M shares⁶	14.3M shares⁷	19.7M shares⁸	23.8M shares⁴	28.6M shares³	84.3M shares³

Cash from operations⁵⁶⁷⁸⁴³$1.9M in 2022

Share buybacks¹¹⁵⁶$50.0K in 2018+0% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash from operations	-$1.5M⁵	-$5.6M⁶	-$6.5M⁷	-$4.1M⁸	-$6.2M⁴	-$4.3M³	$1.9M³
Stock-based compensation						$2.3M³	$392.0K³
Cash from investing							-$3.1M³
Share buybacks	$50.0K¹¹	$50.0K⁵	$50.0K⁶
Cash from financing						$4.5M³	$907.8K³
Dividend per share

Compare Q BioMed Inc. with another company

Corporate structure

Q BioMed Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Q BioMed Inc.

YA II PN, Ltd. Filed SC 13G/A on Q BioMed Inc., latest Nov 4, 2024 (3 filings since Jan 11, 2022)
Ari Jatwes Filed SC 13G/A on Q BioMed Inc., latest Jun 1, 2022

Q BioMed Inc. New York, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Q BioMed Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

Item	Latest	A year before	Change
Long-term investments	$3.1M³ Nov 30, 2022

Intangibles and goodwill

Item	Latest	A year before	Change
Finite-lived intangibles, net	$300.0K³ Nov 30, 2022	$350.0K³ Nov 30, 2021	−14.3%

Inventory

Item	Latest	A year before	Change
Inventory, total	$22.3K³ Nov 30, 2021

Leadership

Who has led Q BioMed Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Denis Corin2016–2022

20202025

Chief executive officerDenis Corin Feb 3, 2016 to May 31, 2022¹²

Board members and other officers (4)

Board memberRick Panicucci Feb 26, 2018 to Jan 17, 2020¹³
Board memberWilliam S. Rosenstadt Jan 25, 2016 to May 31, 2022¹⁴
Board memberDenis Corin Feb 3, 2016 to May 31, 2022¹²
General counselWilliam S. Rosenstadt Dec 14, 2016 to May 31, 2022¹⁵

Former names

ISMO Tech Solutions, Inc.Jan 13, 2014 to Jul 15, 2015²

Timeline

Jun 16, 20238-K Other events¹⁶
May 26, 20238-K Other events¹⁷
Nov 18, 20228-K Unregistered sale of shares; Change to shareholders' rights; Bylaws or fiscal year changed¹⁸
May 13, 20228-K Unregistered sale of shares¹⁹
Jan 25, 20228-K Entered a material agreement; Unregistered sale of shares²⁰
Oct 7, 20218-K Entered a material agreement; Unregistered sale of shares²¹
Feb 3, 2016New chief executive Denis Corin becomes CEO¹²

Filings

30 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 6 major events, 2 insider forms, 4 large holders, 10 other. The latest 20:

Apr 2, 2026REVOKED EDGAR
Nov 4, 2024SC 13G/A EDGAR
Sep 7, 2023UPLOAD EDGAR
Aug 10, 2023UPLOAD EDGAR
Jul 3, 2023UPLOAD EDGAR
Jun 23, 202310-Q/A EDGAR
Jun 16, 202310-Q EDGAR
Jun 16, 20238-K EDGAR
May 26, 202310-K EDGAR
May 26, 20238-K EDGAR
Mar 1, 2023NT 10-K EDGAR
Jan 3, 2023SC 13G/A EDGAR
Dec 7, 2022DEF 14C EDGAR
Nov 18, 20228-K EDGAR
Nov 18, 2022PRE 14C EDGAR
Nov 3, 202210-Q EDGAR
Oct 17, 2022NT 10-Q EDGAR
Oct 6, 2022RW EDGAR
Jul 28, 202210-Q EDGAR
Jul 15, 2022NT 10-Q EDGAR

The 30 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

YA II PN, Ltd.SC 13G/A, 3 filings Jan 11, 2022 to Nov 4, 2024²²
Ari JatwesSC 13G/A, 1 filing Jun 1, 2022²³

SEC filer profile

How Q BioMed Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARQ BioMed Inc.¹
CIK0001596062
Employer ID (EIN)46-4013793¹
Filer statusNon-accelerated filer<br>smaller reporting company¹
Incorporated inNevada¹
Fiscal year endsNovember 30¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
Business address366 Madison Ave., 3Rd Floor, New York, NY 10017¹
Phone212-588-0022¹
Shares outstanding145,094,531 as of Jun 15, 2023¹⁰
Public float$1.3M as of May 24, 2023³
On EDGAR sinceJan 13, 2014¹
Filings215 in all: 8-K (42), 4 (32), 10-Q (28), 10-K (9), 10-Q/A (8), CORRESP (8), EFFECT (8), NT 10-Q (8)¹
All 29 form types
S-1 (8), UPLOAD (8), 424B3 (7), S-1/A (7), D (6), SC 13G/A (5), 3 (4), CT ORDER (4), 8-K/A (3), NT 10-K (3), SC 13G (3), 144 (2), 4/A (2), POS AM (2), RW (2), 10-K/A (1), 424B2 (1), 8-A12G (1), DEF 14C (1), PRE 14C (1), REVOKED (1)
Latest filingsAnnual report (10-K) May 26, 2023
Quarterly report (10-Q) Jun 16, 2023
Latest 8-K (8-K) Jun 16, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARQ BioMed Inc. filings on SEC EDGAR
2
SEC EDGARQ BioMed Inc. filings on SEC EDGAR
3
SEC EDGARQ BioMed Inc. 10-K for fiscal 2022
4
SEC EDGARQ BioMed Inc. 10-K for fiscal 2020
5
SEC EDGARQ BioMed Inc. 10-K for fiscal 2016
6
SEC EDGARQ BioMed Inc. 10-K for fiscal 2017
7
SEC EDGARQ BioMed Inc. 10-K for fiscal 2018
8
SEC EDGARQ BioMed Inc. 10-K for fiscal 2019
9
SEC EDGARQ BioMed Inc. 10-Q for fiscal 2022
10
SEC EDGARQ BioMed Inc. 10-Q for fiscal 2023
11
SEC EDGARQ BioMed Inc. 10-K for fiscal 2016
12
SEC EDGARDenis Corin, Chief executive officer
13
SEC EDGARRick Panicucci, Board member
14
SEC EDGARWilliam S. Rosenstadt, Board member
15
SEC EDGARWilliam S. Rosenstadt, General counsel
16
SEC EDGAROther events
17
SEC EDGAROther events
18
SEC EDGARUnregistered sale of shares; Change to shareholders' rights; Bylaws or fiscal year changed
19
SEC EDGARUnregistered sale of shares
20
SEC EDGAREntered a material agreement; Unregistered sale of shares
21
SEC EDGAREntered a material agreement; Unregistered sale of shares
22
SEC EDGARYA II PN, Ltd. SC 13G/A on Q BioMed Inc.
23
SEC EDGARAri Jatwes SC 13G/A on Q BioMed Inc.
24
SEC EDGARQ BioMed Inc. filing with the SEC